The latest July 2026 retatrutide update is here—and it is not a small one. Two new Phase 3 trials reported average weight loss above 20% at the highest studied doses, even in people with serious weight-related health conditions.
THE LATEST JULY 2026 RETATRUTIDE PHASE 3 RESULTS REACHED UP TO 22.6% AVERAGE WEIGHT LOSS AT 80 WEEKS.
In TRIUMPH-2, the highest-dose group lost an average of 20.8%, or 49.6 pounds. In TRIUMPH-3, the highest-dose group lost an average of 22.6%, or 55.8 pounds. Both results were measured at 80 weeks.
Those are not early guesses. They come from two large, randomized Phase 3 trials that included more than 3,100 people combined. Here is what the numbers mean without the medical-school language.
See Certiva retatrutide research specifications →
What did the two new trials find?
Both trials lasted 80 weeks, but they studied different groups of people.
TRIUMPH-2
20.8% average weight loss
Highest studied dose in adults with type 2 diabetes and obesity or overweight.
TRIUMPH-3
22.6% average weight loss
Highest studied dose in adults with severe obesity and heart disease.
Why it matters
Two difficult populations
Retatrutide met the main weight-loss goal in both Phase 3 trials.
What are the latest July 2026 retatrutide Phase 3 results?
Lilly announced the new topline results on July 23, 2026. The two trials tested retatrutide against placebo for 80 weeks.
| Phase 3 trial | Who participated? | Highest-dose average at 80 weeks | Placebo average |
|---|---|---|---|
| TRIUMPH-2 | Adults with type 2 diabetes and obesity or overweight | −20.8% / −49.6 lb | −4.0% / −9.3 lb |
| TRIUMPH-3 | Adults with severe obesity and established cardiovascular disease | −22.6% / −55.8 lb | −3.2% / −7.7 lb |
The headline is simple: the highest-dose retatrutide groups averaged more than 20% weight loss in both trials.
That does not mean every participant lost the same amount. Trial averages combine many individual results. But the size and consistency of the averages make these results important.
Read the complete Lilly Phase 3 announcement for the company’s full tables and study descriptions.
What happened in TRIUMPH-2?
TRIUMPH-2 included 1,152 adults with type 2 diabetes and obesity or overweight. Participants were assigned to retatrutide at one of three target doses or to placebo.
| TRIUMPH-2 group | Average body-weight change at 80 weeks |
|---|---|
| Retatrutide 4 mg | −12.7% |
| Retatrutide 9 mg | −19.1% |
| Retatrutide 12 mg | −20.8% |
| Placebo | −4.0% |
The highest-dose group also lost an average of 49.6 pounds. Average A1C reductions reached up to 1.6 percentage points, giving the trial a second clear metabolic result alongside weight loss.
The big advantage of this result is the population. Weight loss can be more difficult for people with type 2 diabetes, yet the two higher-dose groups still averaged roughly 19% to 21% at 80 weeks.
What happened in TRIUMPH-3?
TRIUMPH-3 included 1,949 adults with severe obesity and established cardiovascular disease. Some had type 2 diabetes and some did not.
| TRIUMPH-3 group | Average body-weight change at 80 weeks |
|---|---|
| Retatrutide 9 mg | −21.6% |
| Retatrutide 12 mg | −22.6% |
| Placebo | −3.2% |
At the highest studied dose, participants lost an average of 55.8 pounds and 7.5 inches from the waist. Lilly also reported average reductions in several cardiovascular risk markers, including:
- 37.0% in triglycerides;
- 16.5% in non-HDL cholesterol; and
- 9.3 mmHg in systolic blood pressure.
Weight was the main endpoint, but these additional numbers make TRIUMPH-3 more than a scale-only story.
Why is retatrutide called a triple agonist?
Retatrutide is one peptide molecule designed to activate three receptor systems:
- GIP
- GLP-1
- Glucagon
Think of them as three different message receivers. Retatrutide is engineered to send a signal to all three.
GLP-1 and GIP are connected with fullness, food intake, and the body’s response to glucose. The glucagon receptor adds a third pathway connected with energy use and metabolism. That three-part design is the main reason retatrutide attracts so much attention.
For comparison:
- Semaglutide activates GLP-1.
- Tirzepatide activates GIP and GLP-1.
- Retatrutide activates GIP, GLP-1, and glucagon.
See our plain-English semaglutide vs tirzepatide comparison for the difference between the established single- and dual-receptor options. For the direct next-generation comparison, see retatrutide vs tirzepatide in July 2026.
What side effects were reported?
The most common side effects were digestive, which is also common across the broader GLP-1 category.
In the new retatrutide trials, the most frequently reported events included:
- diarrhea;
- nausea;
- constipation;
- decreased appetite; and
- vomiting.
Lilly said these events were generally mild to moderate, and most resolved during treatment. That is the most useful simple conclusion: the trials reported strong average results, while the most common side effects were mainly digestive and usually temporary.
Is retatrutide FDA approved?
Retatrutide is currently an investigational molecule. The important next step is already visible: Lilly said it plans to submit retatrutide for U.S. approval in the first quarter of 2027.
That puts the new Phase 3 announcement in context. These results are part of the clinical package Lilly plans to take to regulators; they are not an approval announcement.
Certiva’s retatrutide is supplied as a lyophilized laboratory research reference material. It is not a finished prescription medicine and is not for human consumption.
What should a retatrutide research buyer check?
The Phase 3 headline explains why the molecule matters. A buyer still needs to verify the actual research material being offered.
Before choosing a retatrutide supplier, check:
- the exact molecule name and vial specification;
- whether the vial lot matches the Certificate of Analysis;
- HPLC purity and identity information;
- storage, packaging, availability, and lead time;
- stocked, bulk, and custom-quantity options; and
- whether the supplier can answer manufacturing questions directly.
Certiva supplies retatrutide in 5, 10, 15, 20, 30, 40, 50, and 60 mg vial specifications, with 10 vials per standard box. Bulk and custom quantities are available by inquiry.
Our published 2026 retatrutide report lists 99.699% HPLC purity for that specific batch. Buyers can view the published retatrutide COA and request the current applicable report before ordering.
Read our five-minute guide to checking a peptide COA or see how to choose a peptide supplier using seven simple checks.
The bottom line
THE LATEST JULY 2026 RETATRUTIDE PHASE 3 RESULTS REACHED UP TO 22.6% AVERAGE WEIGHT LOSS AT 80 WEEKS.
TRIUMPH-2 reached a 20.8% average in adults with type 2 diabetes and obesity or overweight. TRIUMPH-3 reached a 22.6% average in adults with severe obesity and cardiovascular disease. Both studies met their main weight-loss endpoint.
The reason retatrutide stands out is equally simple: it combines three receptor signals in one peptide molecule, and its Phase 3 program has now delivered strong results in multiple challenging groups.
Request retatrutide specifications, the current COA, and a quote
Tell Certiva the vial specification, quantity, destination country, and documentation requirements. We will reply with current availability, the applicable batch information, lead time, bulk options, and a quote.
View Retatrutide specifications · See published COAs · Visit the Certiva facility page
Request the current Retatrutide COA + a quote →
Sources and further reading
- Lilly: TRIUMPH-2 and TRIUMPH-3 Phase 3 results, July 23, 2026
- ClinicalTrials.gov: TRIUMPH-2, NCT05929079
- ClinicalTrials.gov: TRIUMPH-3, NCT05882045
- World Health Organization: GLP-1 therapies explained
Frequently asked questions
What are the latest July 2026 retatrutide Phase 3 results?
THE LATEST JULY 2026 RETATRUTIDE PHASE 3 RESULTS REACHED UP TO 22.6% AVERAGE WEIGHT LOSS AT 80 WEEKS. The highest-dose group averaged 20.8% in TRIUMPH-2 and 22.6% in TRIUMPH-3.
How much weight did people lose in TRIUMPH-2?
In TRIUMPH-2, participants receiving the highest studied dose lost an average of 20.8% of their starting body weight, or 49.6 pounds, at 80 weeks.
How much weight did people lose in TRIUMPH-3?
In TRIUMPH-3, participants receiving the highest studied dose lost an average of 22.6% of their starting body weight, or 55.8 pounds, at 80 weeks.
What is retatrutide?
Retatrutide is a single peptide molecule designed to activate three receptor systems—GIP, GLP-1, and glucagon. That is why it is called a triple hormone receptor agonist.
Is retatrutide FDA approved?
Retatrutide is still investigational. Lilly said it plans to submit retatrutide for U.S. approval in the first quarter of 2027.
What were the most common side effects in the new trials?
The most common reported side effects included diarrhea, nausea, constipation, decreased appetite, and vomiting. Lilly said these events were generally mild to moderate and most resolved during treatment.
Can buyers request a Certiva retatrutide COA before ordering?
Yes. Buyers can request the current batch COA, vial specifications, availability, lead time, bulk options, and a destination-based quote before placing an order.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.